Humanigen Inc (HGENQ)

[Corundum]

You should read HGEN chart on competitors -- page 44 of their Featured Presentations on their Events and Presentations page. The page number is from the February 1 version of the presentation. They will probably update it as of March 1 when they do their next presentation in a few days.

Mavrilimumab is one of the key GM-CSF competitors still standing. It targets a slightly different point on GM-CSF (the alpha receptor) which may or may not make a difference. The Gilead/Kite study that is testing Lenz with Car-T therapy also includes Mavrilimumab, so Gilead and/or the government may have an idea of who is better. At least Gilead thought they were in the running for Car-T.

They may have made a similar mistake as other competitors have done with low dosage, however. The old rheumatoid arthritis studies for this drug used 50 to 150 milligrams, which is way too low. An earlier Italian study for Covid used a dosage that was per kilogram of body weight, so they may be using 500-600 milligrams in their study. HGEN is using 1800 milligrams (600 per infusion).